Trial Profile
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Local Tolerability and Pharmacokinetic Characteristics After Administration of Eye-drop HL036 in Healthy Korean Male Volunteers (Phase I)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2016
Price :
$35
*
At a glance
- Drugs Tanfanercept (Primary)
- Indications Dry eyes
- Focus Adverse reactions
- Sponsors HanAll Biopharma
- 07 Dec 2016 Status changed from recruiting to completed.
- 01 Apr 2016 New trial record